Science Translational Medicine· Allan C. deCamp, Michal Juraska, Li Li, Craig A. Magaret, Brian D. Williamson, Hongjun Bai, Yunda Huang, Elena E. Giorgi, Lily Zhang, Lindsay N. Carpp, Srilatha Edupuganti, Nyaradzo M. Mgodi, Kevin Gillespie, Beatrix Haddock, Pedro Gonzales, Robinson Cabello, Catherine Orrell, Javier R. Lama, Fatima Laher, Erica M. Lazarus, Jorge Sanchez, Ian Frank, Juan C. Hinojosa, Magdalena E. Sobieszczyk, Pamela G. Mukwekwerere, Joseph Makhema, Lindsey R. Baden, Kelly E. Seaton, John Hural, M. Juliana McElrath, Simbarashe Takuva, April K. Randhawa, Nidhi Kochar, Estelle Piwowar-Manning, Deborah J. Donnell, Nirupama Sista, Philip Andrew, Shelly T. Karuna, James G. Kublin, Glenda E. Gray, Myron S. Cohen, Dan H. Barouch, Georgia D. Tomaras, Morgane Rolland, David C. Montefiori, Lynn Morris, James I. Mullins, Carolyn Williamson, Lawrence Corey, Peter B. Gilbert·· 16 小时前AI 评分23
VRC01预防HIV-1的体内长期活性：初期保护效力与随后发生的突破性感染
Extended in vivo activity of VRC01 HIV-1 prophylaxis entails initial protective efficacy and subsequent breakthrough infections
AI 导读
VRC01用于HIV-1预防时，其体内长期活性表现为初期具有保护效力，随后出现突破性感染。该研究发表于Science Translational Medicine，所提供内容未列出样本量、随访时长或具体效应量。
来源：Science Translational Medicine · science.org